Skip to content

Released Nov 7, 2013, after the close

10-Q filed Nov 7, 2013, 38 days after period end · 0001144204-13-059668

Q3 2013 · 10-Q
Revenue$2.28M−38.7% vs Q3 2012+0.9% vs Q2 2013
Net Income-$5.75MN/M vs Q3 2012N/M vs Q2 2013
EPS Diluted-$0.06N/M vs Q3 2012N/M vs Q2 2013
Gross Profit$1,772,000−41.4%
Operating Income-$5,645,000N/M
Operating Cash Flowderived-$8,216,000N/M
Free Cash Flowderived-$8,543,000N/M
Margins · derived
Gross margin77.6%−3.6 pt vs Q3 2012
Operating margin-247.2%−97.9 pt vs Q3 2012
Net margin-251.6%−104.5 pt vs Q3 2012

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2013Q3 2012Q3 2011Q3 2010
Revenue$2.28M$3.72M$1.13M$3.18M
Net Income-$5.75M-$5.48M-$8.88M-$2.47M
EPS Diluted-$0.06$0.06-$0.10$0.03

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR